Business Context and Reporting Period
This Form 8-K Current Report was filed by Shuttle Pharmaceuticals Holdings, Inc. on June 13, 2024. The filing primarily addresses executive leadership changes, specifically the appointment of a new Chief Financial Officer (CFO) and the transition of the current CFO to a different role.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. As a Form 8-K focused on corporate governance and personnel, it contains no financial performance data for the reporting period.
Material Changes
The material change reported is the appointment of Mr. Timothy J. Lorber as the Company's Chief Financial Officer. The transition is structured as follows:
- Transition Period: Mr. Lorber serves as part-time CFO from June 13, 2024, until September 9, 2024.
- Full-Time Role: Effective September 10, 2024, Mr. Lorber assumes the full-time CFO role.
- Departure: Current CFO Mr. Michael Vander Hoek will transition out of the CFO role on September 10, 2024, to serve full-time as Vice President, Regulatory.
Compensation and Management Commentary
Management highlighted Mr. Lorber's extensive background, including over 40 years of finance experience, 15 years at Legg Mason, Inc., and roles at Freddie Mac. The compensation package for Mr. Lorber includes:
- Base Salary: $227,000 per annum (50% during the transition period; 100% starting September 10, 2024).
- Equity Grant: 227,635 restricted stock units (RSUs) vesting annually over three years.
- Bonus: Eligibility for a milestone-based bonus of up to $72,000.
- Benefits: Standard health insurance and vacation benefits.
No specific risks, contingencies, or unusual items were disclosed in this filing beyond the standard executive transition.
Investor Verification Checklist
- Verify the vesting schedule and performance conditions for the 227,635 RSUs granted to Mr. Lorber.
- Confirm the exact date of the transition (September 10, 2024) for the handover of CFO duties.
- Review the full text of the Employment Agreement (Exhibit 10.1) for any additional severance or termination clauses not summarized here.
- Monitor future filings for the impact of this leadership change on the company's financial reporting and regulatory strategy.